Stephen C Piscitelli
Overview
Explore the profile of Stephen C Piscitelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gold L, Del Rosso J, Ehst B, Zirwas M, Green L, Brown P, et al.
J Dermatolog Treat
. 2025 Jan;
36(1):2444489.
PMID: 39799945
Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We...
2.
Simpson E, Hebert A, Browning J, Serrao R, Sofen H, Brown P, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(1):111-124.
PMID: 39777610
Introduction: Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream...
3.
Silverberg J, Eichenfield L, Hebert A, Simpson E, Gold L, Bissonnette R, et al.
J Am Acad Dermatol
. 2024 May;
91(3):457-465.
PMID: 38777187
Background: Tapinarof cream 1% once daily (QD), a topical aryl hydrocarbon receptor agonist, downregulates pro-inflammatory Th2 cytokines, upregulates skin-barrier components, and reduces oxidative stress. Objective: To assess tapinarof efficacy and...
4.
Strober B, Gold L, Bissonnette R, Armstrong A, Kircik L, Tyring S, et al.
J Am Acad Dermatol
. 2022 Jun;
87(4):800-806.
PMID: 35772599
Background: Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle and well tolerated in two 12-week phase 3 trials in adults with mild...
5.
Lebwohl M, Gold L, Strober B, Papp K, Armstrong A, Bagel J, et al.
N Engl J Med
. 2021 Dec;
385(24):2219-2229.
PMID: 34879448
Background: Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin....
6.
Jett J, McLaughlin M, Lee M, Parish L, DuBois J, Raoof T, et al.
Am J Clin Dermatol
. 2021 Oct;
23(1):83-91.
PMID: 34713415
Background: Tapinarof is a novel topical therapeutic aryl hydrocarbon receptor modulating agent in development for the treatment of psoriasis and atopic dermatitis. Objective: This multicenter, open-label trial assessed the safety,...
7.
Piscitelli S, Pavel A, McHale K, Jett J, Collins J, Gillmor D, et al.
J Invest Dermatol
. 2021 Jan;
141(7):1847-1851.
PMID: 33493530
No abstract available.
8.
Song I, Borland J, Savina P, Chen S, Patel P, Wajima T, et al.
Clin Pharmacol Drug Dev
. 2015 Jun;
2(4):342-348.
PMID: 26097786
This study evaluated dolutegravir pharmacokinetics (PK) in subjects with moderate hepatic impairment compared to matched, healthy controls. In this open-label, parallel-group study, eight adult subjects with moderate hepatic impairment (Child-Pugh...
9.
Song I, Borland J, Chen S, Wajima T, Peppercorn A, Piscitelli S
Ann Pharmacother
. 2015 Apr;
49(7):784-9.
PMID: 25862012
Background: Dolutegravir (DTG; Tivicay; ViiV Healthcare, Research Triangle Park, NC) is an HIV-1-unboosted integrase inhibitor with no cytochrome P450 or uridine 5'diphosphate-glucuronosyltransferase inhibition or induction. As DTG is administered to...
10.
Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli S
Antimicrob Agents Chemother
. 2014 Aug;
58(11):6696-700.
PMID: 25155604
Dolutegravir (DTG) is an HIV integrase inhibitor (INI) with demonstrated activity in INI-naive and INI-resistant patients. The objective of this open-label, 2-period, single-sequence study was to evaluate the effect of...